A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

This Phase 1 study tests a combination of two treatments: a personalized cancer vaccine (made from fusing a patient's own immune cells called dendritic cells with their myeloma cells) and a drug called elranatamab, for people with multiple myeloma (a blood cancer) that has relapsed or stopped responding to prior therapies. **You may be eligible if...** - You are 18 or older and have a confirmed diagnosis of multiple myeloma - Your cancer has relapsed or stopped responding to treatment, including prior treatment with proteasome inhibitors, immunomodulatory drugs (IMiDs), and an anti-CD38 antibody - You have received at least 3 prior lines of therapy - You have more than 20% plasma cells (myeloma cells) in your bone marrow - Your blood counts and organ function meet minimum thresholds **You may NOT be eligible if...** - You have received fewer than 3 prior lines of therapy - You have poor organ function or very low blood counts - You have active serious infections or other conditions making treatment unsafe Talk to your doctor to see if this trial is right for you.